Supernus Pharmaceuticals Return on Tangible Equity 2012-2026 | SUPN
Current and historical return on tangible equity values for Supernus Pharmaceuticals (SUPN) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Supernus Pharmaceuticals Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2026-03-31 | $-0.04B | $0.40B | -9.30% |
| 2025-09-30 | $-0.02B | $0.40B | -5.06% |
| 2025-06-30 | $0.06B | $0.41B | 15.51% |
| 2025-03-31 | $0.06B | $0.36B | 16.94% |
| 2024-12-31 | $0.07B | $0.32B | 23.17% |
| 2024-09-30 | $0.06B | $0.27B | 22.10% |
| 2024-06-30 | $0.01B | $0.22B | 2.29% |
| 2024-03-31 | $-0.02B | $0.18B | -8.74% |
| 2023-12-31 | $0.00B | $0.15B | 0.65% |
| 2023-09-30 | $0.03B | $0.12B | 24.42% |
| 2023-06-30 | $0.05B | $0.08B | 56.29% |
| 2023-03-31 | $0.06B | $0.04B | 127.27% |
| 2022-12-31 | $0.07B | $0.00B | 2166.67% |
| 2022-09-30 | $0.04B | $-0.04B | -107.80% |
| 2022-06-30 | $0.06B | $0.06B | 100.00% |
| 2022-03-31 | $0.07B | $0.15B | 49.01% |
| 2021-12-31 | $0.05B | $0.24B | 22.20% |
| 2021-09-30 | $0.08B | $0.34B | 24.38% |
| 2021-06-30 | $0.10B | $0.30B | 33.86% |
| 2021-03-31 | $0.11B | $0.25B | 44.44% |
| 2020-12-31 | $0.13B | $0.32B | 40.00% |
| 2020-09-30 | $0.13B | $0.39B | 33.59% |
| 2020-06-30 | $0.12B | $0.47B | 25.56% |
| 2020-03-31 | $0.12B | $0.55B | 21.41% |
| 2019-12-31 | $0.11B | $0.51B | 22.09% |
| 2019-09-30 | $0.11B | $0.47B | 22.35% |
| 2019-06-30 | $0.11B | $0.44B | 23.93% |
| 2019-03-31 | $0.10B | $0.41B | 25.46% |
| 2018-12-31 | $0.11B | $0.37B | 29.90% |
| 2018-09-30 | $0.10B | $0.32B | 30.60% |
| 2018-06-30 | $0.09B | $0.28B | 31.07% |
| 2018-03-31 | $0.07B | $0.24B | 30.32% |
| 2017-12-31 | $0.06B | $0.21B | 27.70% |
| 2017-09-30 | $0.06B | $0.19B | 30.52% |
| 2017-06-30 | $0.10B | $0.17B | 59.71% |
| 2017-03-31 | $0.10B | $0.15B | 65.75% |
| 2016-12-31 | $0.09B | $0.12B | 74.59% |
| 2016-09-30 | $0.08B | $0.11B | 80.00% |
| 2016-06-30 | $0.03B | $0.08B | 32.10% |
| 2016-03-31 | $0.02B | $0.08B | 23.84% |
| 2015-12-31 | $0.01B | $0.07B | 19.65% |
| 2015-09-30 | $0.01B | $0.06B | 18.49% |
| 2015-06-30 | $0.01B | $0.05B | 9.62% |
| 2015-03-31 | $0.01B | $0.04B | 14.46% |
| 2014-12-31 | $-0.01B | $0.03B | -34.11% |
| 2014-09-30 | $-0.04B | $0.03B | -122.31% |
| 2014-06-30 | $-0.06B | $0.03B | -233.66% |
| 2014-03-31 | $-0.09B | $0.03B | -335.85% |
| 2013-12-31 | $-0.09B | $0.03B | -303.33% |
| 2013-09-30 | $-0.08B | $0.04B | -228.97% |
| 2013-06-30 | $-0.07B | $0.04B | -183.44% |
| 2013-03-31 | $-0.06B | $0.04B | -138.36% |
| 2012-12-31 | $-0.05B | $0.03B | -160.68% |
| 2012-09-30 | $0.05B | $0.02B | 284.06% |
| 2012-06-30 | $0.05B | $0.01B | 453.33% |
| 2012-03-31 | $0.05B | $0.00B | 2650.00% |
| 2011-12-31 | $0.05B | $0.00B | 2266.67% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.918B | $0.719B |
| Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |